Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2015-03-02

FDA Approved: BREO ELLIPTA — Supplemental Application (GlaxoSmithKline LLC)

View source ↗

Summary

The FDA approved a supplemental application for BREO ELLIPTA (fluticasone furoate and vilanterol trifenatate) submitted by GlaxoSmithKline LLC, authorizing chan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BREO ELLIPTA (fluticasone furoate and vilanterol trifenatate)

Snippet

SUPPL AP for BREO ELLIPTA (FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE)